1. Home
  2. NNNN vs DVAX Comparison

NNNN vs DVAX Comparison

Compare NNNN & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

N/A

Current Price

$27.70

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo Dynavax Technologies Corporation

DVAX

Dynavax Technologies Corporation

HOLD

Current Price

$10.83

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NNNN
DVAX
Founded
2021
1996
Country
Germany
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2025
2004

Fundamental Metrics

Financial Performance
Metric
NNNN
DVAX
Price
$27.70
$10.83
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$26.50
AVG Volume (30 Days)
26.9K
1.5M
Earning Date
04-28-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.06
N/A
Revenue
$8,185,146.00
$330,514,000.00
Revenue This Year
N/A
$24.63
Revenue Next Year
N/A
$15.85
P/E Ratio
$534.57
N/A
Revenue Growth
21.95
26.73
52 Week Low
$5.18
$9.20
52 Week High
$55.65
$14.63

Technical Indicators

Market Signals
Indicator
NNNN
DVAX
Relative Strength Index (RSI) 48.35 48.18
Support Level $26.89 $10.76
Resistance Level $44.73 $11.00
Average True Range (ATR) 5.78 0.25
MACD -0.21 -0.06
Stochastic Oscillator 29.62 20.53

Price Performance

Historical Comparison
NNNN
DVAX

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: